Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Fineline Cube Sep 10, 2026
Company Deals PIC

METiS Life Sciences and JOINN Biologics Form JOINMETiS Biopharma Joint Venture – Integrated mRNA Therapeutics R&D and Manufacturing Platform

Fineline Cube Sep 10, 2026
Company Drug PIC

Merck Launches Clesrovimab in China – World’s First Single Fixed‑Dose, Long‑Acting RSV Monoclonal Antibody Now Commercially Available for Infant Protection

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Fineline Cube Sep 10, 2026
Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Fineline Cube Sep 10, 2026
Company

Novartis China’s Business Growth Lead Zhu Jiakang Departs for Personal Reasons

Fineline Cube Aug 4, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has seen the departure of Zhu Jiakang, who led...

Company

BeiGene’s Q2 2023 Financial Report Highlights 81.8% YOY Product Revenue Growth

Fineline Cube Aug 3, 2023

China-based biotech company BeiGene (SHA: 688235, HKG: 6160, NASDAQ: BGNE) has released its financial report...

Legal / IP Policy / Regulatory

National Health Commission’s Anti-Corruption Drive Impacts China’s Pharmaceutical Sector

Fineline Cube Aug 3, 2023

An anti-corruption crackdown announced by the National Health Commission (NHC) at the end of July...

Company Medical Device

Our United Corporation’s Linear Accelerator Approved as Innovative Medical Device by NMPA

Fineline Cube Aug 3, 2023

Xi’an-based Our United Corporation has announced that its medical electronic linear accelerator has been approved...

Company Drug

CORXEL Gets CDE Approval for Phase III Presbyopia Trials of LNZ100 and LNZ101

Fineline Cube Aug 3, 2023

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has announced that...

Company Deals

Lee’s Pharmaceutical Subsidiary Zhaoke Ophthalmology Partners with Eyebright Medical Technology

Fineline Cube Aug 3, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has entered...

Company Deals

BeiGene and Bristol-Myers Squibb/Celgene Settle Partnership, Termination Set for 2023

Fineline Cube Aug 3, 2023

BeiGene (NASDAQ: BGNE) has announced a settlement and termination agreement with US firm Bristol-Myers Squibb/Celgene...

Company Medical Device

Suzhou Jiecheng Medical Secures FDA BDD for Transvascular Aortic Valve Treatment

Fineline Cube Aug 3, 2023

Suzhou Jiecheng Medical Technology Co., Ltd has announced that it has obtained Breakthrough Devices Designation...

Company Drug

ABM Therapeutics’ ABM-1310 Earns Orphan Drug Designation for BRAF V600 Mutant Glioblastoma

Fineline Cube Aug 3, 2023

Shanghai-based ABM Therapeutics Inc. has announced that it has received Orphan Drug Designation (ODD) from...

Company Deals

Huaboron Neutron Technology Secures Over RMB 100 Million in Angel Financing for BNCT System

Fineline Cube Aug 3, 2023

Huaboron Neutron Technology (Hangzhou) Co., Ltd (HBNCT) has reportedly secured more than RMB 100 million...

Company Deals

ICE Bioscience Secures Series B+ Financing to Boost Integration Capabilities

Fineline Cube Aug 3, 2023

Beijing-based Contract Research Organization (CRO) ICE Bioscience has reportedly raised close to RMB 100 million...

Company Drug

Sumitomo Pharma and Otsuka’s Ulotaront Fails to Meet Primary Endpoint in Schizophrenia Trials

Fineline Cube Aug 3, 2023

Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) and Otsuka Pharmaceutical Co., Ltd (FRA: OS1) have...

Company

Siemens Healthineers Reports 3.6% YOY Revenue Growth in Q3 2023 Financials

Fineline Cube Aug 3, 2023

Germany-based life sciences giant Siemens Healthineers AG (ETR: SHL) has released its financial results for...

Company Deals

Biogen Inc. to Acquire Reata Pharmaceuticals in $7.3 Billion Deal

Fineline Cube Aug 2, 2023

US-based Biogen Inc., (NASDAQ: BIIB) has announced that it has reached an agreement to fully...

Company

Pfizer Inc. Reports Q2 2023 Revenues, Signals Shift Beyond COVID-19 Products

Fineline Cube Aug 2, 2023

US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the second...

Company Deals

EQRx Inc. to be Acquired by Revolution Medicines in All-Stock Transaction

Fineline Cube Aug 2, 2023

US-based EQRx Inc. (NASDAQ: EQRX) has revealed that a definitive agreement has been signed for...

Company Deals

GSK Partners with Zuellig Pharma for Vaccine Distribution and Cold-Chain Management in Asia-Pacific

Fineline Cube Aug 2, 2023

GlaxoSmithKline (GSK; NYSE: GSK), a leading global vaccine manufacturer, has signed an agreement with Philippines-based...

Company Drug

Luye Pharma’s Parkinson’s Disease Treatment LY03003 Receives NMPA Review Acceptance

Fineline Cube Aug 2, 2023

Luye Pharma Group (HKG: 2186) has announced that the National Medical Products Administration (NMPA) has...

Company Deals

Mabwell Bioscience Secures Licensing Deals for Denosumab Biosimilars in Egypt and Pakistan

Fineline Cube Aug 2, 2023

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced separate licensing and commercialization agreements...

Company Deals

GeneMind Biosciences Secures RMB 400 Million in Series C Financing to Expand Gene Testing

Fineline Cube Aug 2, 2023

Shenzhen-based DNA sequencer specialist, GeneMind Biosciences Co., Ltd, has reportedly raised RMB 400 million in...

Posts pagination

1 … 546 547 548 … 719

Recent updates

  • Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone
  • Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline
  • Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis
  • Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404
  • NMPA Accepts Hengrui’s New Drug Application for Ribupatide Injection – Dual GLP‑1/GIP Receptor Agonist Nears Approval for Type 2 Diabetes in China
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

Novo Nordisk’s Sogroya (Somapacitan) Wins NMPA Approval for Three New Pediatric Indications – Now China’s Broadest‑Label Long‑Acting Growth Hormone

Company Deals PIC

Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Company Drug PIC

Novo Nordisk’s Wegovy Wins NMPA Approval for MASH in China – First and Only GLP‑1 Receptor Agonist Indicated for Metabolic Dysfunction‑Associated Steatohepatitis with F2–F3 Fibrosis

Company Deals

Adagene Achieves New Milestone in SAFEbody ADC Collaboration with Exelixis – USD 2 Million Payment Triggered by Preclinical Progress of ROR1/2‑Targeted XB404

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.